Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets

Parkinson's Disease Clinical Trial

— PLKS-BE  

Official title:

Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04275492
• Other study ID #: ZYYY-PLKS-BE-2019-02
• Status: Terminated
• Phase: N/A
• Start date: July 24, 2020
• Est. completion date: December 1, 2020

Study information

• Verified date: November 2019
• Source: First Affiliated Hospital of Zhejiang University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of In two kinds of fasting and postprandial Chinese healthy subjects with Boehringer represent Ingelheim company production of hydrochloric acid Pramipexole zyban (specification: 0.26 mg/piece, in Pramipexole, commodity name: Siforl ®) as the reference preparation, study a single oral dose of macro crown biological pharmaceutical co., LTD. Production of Pramipexole Dihydrochloride Sustained Release Tablets (specification:The pharmacokinetic parameters of the drug were calculated after the time course of the drug in vivo (0.375mg/ tablet, as measured by pramipexole hydrochloride), and the human relative bioavailability of the two preparations were compared to evaluate their bioequivalence. A secondary purpose To evaluate the safety of fasting and postprandial oral test preparations and reference preparations.

Description:

In this study, a single-center, randomized, open, two-cycle, self-crossover, single-dose administration design was used to evaluate the bioequivalence of the tested preparations and reference preparations given to Chinese healthy subjects with single-dose, fasting and post-meal administration of Pramipexole Dihydrochloride Sustained Release Tablets. This study was divided into two parts: fasting administration and high-fat post-meal administration.The healthy subjects were randomly divided into two groups with the same number of patients in each group. The washing period was 7±1 days. In this study, venous blood was collected at 18 time points (fasting and postprandial) within 1h (0h) before administration and at 1.0h, 2.0h, 3.0h, 4.0h, 5.0h, 6.0h, 7.0h, 8.0h, 9.0h, 10.0h, 11.0h, 12.0h, 16.0h, 36.0h, 48.0h, and 72.0h after administration. A total of 60 healthy subjects were enrolled into the equivalence test, among which: 1. Study on human bioequivalence of drug administration on an empty stomach: 30 healthy subjects (male and female). 2. Human bioequivalence of high-fat post-meal administration: 30 healthy subjects (male and female).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 30
• Est. completion date: December 1, 2020
• Est. primary completion date: October 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Subjects are fully aware of the purpose, nature, methods, and possible adverse effects of the test, volunteer as a subject, and sign the informed consent form before the start of any research program, and ensure that any program will be involved in the study;
• Male and female subjects aged 18-45 years (including 18 and 45 years);
• Male body weight =50.0 kg, female body weight =45.0 kg;Body mass index [BMI= weight (kg)/ height (m)2] is within the range of 19.0~26.0 kg/m2 (including critical value);
• According to the previous medical history, vital signs, comprehensive physical examination and required laboratory examination, the investigator determines that the patient is a healthy subject;
• Fully understand the purpose of the test, the nature of the test, the research procedures and possible adverse reactions, voluntarily participate in the test and sign the informed consent (the process of obtaining the informed consent conforms to the GCP regulations);
• The subject will be able to communicate well with the investigator, understand and comply with the requirements of this study, and be willing to be admitted to the phase I clinical research ward as required.

Exclusion Criteria:

• Have a history of allergy to this drug component or similar species;Had a history of allergy to two or more drugs, food, etc.;
• Have a history of dysphagia or any gastrointestinal diseases that affect drug absorption;
• Patients with any history of clinically serious diseases, including but not limited to diseases of digestive system, cardiovascular system, respiratory system, urinary system, musculoskeletal system, endocrine system, neuropsychiatric system, blood system, immune system and metabolic abnormalities, which are clinically significant as judged by the investigator;
• Those who cannot tolerate venipuncture and have a history of acupuncture and blood sickness;
• Those who have received surgery (except appendicitis) within 3 months before screening, or who plan to have surgery during the study, and those who have received surgery that will affect drug absorption, distribution, metabolism and excretion;
• Screening those who had a history of drug abuse within the previous 6 months;
• Used drugs within 3 months before screening;
• Have participated in clinical trials of other drugs within 3 months before administration;
• Screening for blood donation within the first 3 months, including ingredient blood or massive blood loss (=200mL), who received blood transfusion or used blood products;
• Have used any prescription drugs, non-prescription drugs, Chinese herbal medicine and vitamins within 2 weeks before administration;
• Those who smoked more than 5 cigarettes per day in the first 3 months or could not stop using any tobacco products during the trial;
• Those who drank more than 14 units of alcohol per week (1 unit of alcohol ˜360 mL beer or 45 mL spirits with a 40% alcohol content or 150 mL wine) in the first 3 months or who could not abstain from alcohol during the trial;
• People who drank excessive amounts of tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup =250 mL) every day for 3 months before screening;Or within 48 hours before the test, eat any food containing alcohol or rich in xanthine compounds (such as chocolate) and drink (such as tea, coffee, cola, etc.), grapefruit juice, etc;
• Lactose intolerant;
• Those who have special requirements on diet and cannot accept a uniform diet;
• The test of hepatitis b surface antigen, hepatitis c virus antibody, anti-human immunodeficiency virus antibody or anti-syphilis spirochete specific antibody has one or more clinical significance;
• Women who have positive pregnancy test results and are lactating, pregnant or planning to have a recent pregnancy;
• Those with positive alcohol test results or positive screening for drug abuse (morphine, methamphetamine, ketamine, dimethylene dioxymethamphetamine and tetrahydrocannabinic acid);
• Other subjects deemed unsuitable by the investigator.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Drug:
• Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)
Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD
• Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)
Siforl® is produced by Boehringer Ingelheim International Gmbh

Locations

Country	Name	City	State
China	The First Affiliated Hospital,ZheJiang Univercity	Hanzhou	Zhejiang

Sponsors (2)

Lead Sponsor	Collaborator
First Affiliated Hospital of Zhejiang University	Hongguan biological pharmaceutical co.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax	Maximum observed plasma concentration	[time range: 72 hours post-dose on Day 1,8]
Primary	Tmax	Time to maximum plasma concentration	[time range: 72 hours post-dose on Day 1,8]
Primary	AUC(0-inf)	Area under a time curve of plasma concentration from time 0 to infinity	[time range: 72 hours post-dose on Day 1,8]
Primary	AUC(0-72h)	Area under the concentration-time curve 0 to 72 h after administration	[time range: 72 hours post-dose on Day 1,8]